[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RS61016B1 - Prolekovi inhibitora hiv reverzne transkriptaze - Google Patents

Prolekovi inhibitora hiv reverzne transkriptaze

Info

Publication number
RS61016B1
RS61016B1 RS20201323A RSP20201323A RS61016B1 RS 61016 B1 RS61016 B1 RS 61016B1 RS 20201323 A RS20201323 A RS 20201323A RS P20201323 A RSP20201323 A RS P20201323A RS 61016 B1 RS61016 B1 RS 61016B1
Authority
RS
Serbia
Prior art keywords
prodrugs
reverse transcriptase
transcriptase inhibitors
hiv reverse
hiv
Prior art date
Application number
RS20201323A
Other languages
English (en)
Inventor
Christopher S Burgey
Jeffrey F Fritzen
Jaume Balsells
Mehul Patel
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of RS61016B1 publication Critical patent/RS61016B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RS20201323A 2014-04-01 2015-03-27 Prolekovi inhibitora hiv reverzne transkriptaze RS61016B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461973689P 2014-04-01 2014-04-01
EP15774282.6A EP3125894B1 (en) 2014-04-01 2015-03-27 Prodrugs of hiv reverse transcriptase inhibitors
PCT/US2015/022868 WO2015153304A1 (en) 2014-04-01 2015-03-27 Prodrugs of hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
RS61016B1 true RS61016B1 (sr) 2020-12-31

Family

ID=54241131

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20201323A RS61016B1 (sr) 2014-04-01 2015-03-27 Prolekovi inhibitora hiv reverzne transkriptaze

Country Status (21)

Country Link
US (1) US10004740B2 (sr)
EP (2) EP3125894B1 (sr)
JP (1) JP6342011B2 (sr)
KR (1) KR102440843B1 (sr)
CN (1) CN106456639B (sr)
AU (1) AU2015241247B2 (sr)
BR (1) BR112016022722B8 (sr)
CA (1) CA2944187C (sr)
CY (1) CY1123582T1 (sr)
DK (1) DK3125894T3 (sr)
ES (1) ES2828951T3 (sr)
HR (1) HRP20201780T1 (sr)
HU (1) HUE051848T2 (sr)
LT (1) LT3125894T (sr)
MX (1) MX2016012915A (sr)
PL (1) PL3125894T3 (sr)
PT (1) PT3125894T (sr)
RS (1) RS61016B1 (sr)
RU (1) RU2693622C2 (sr)
SI (1) SI3125894T1 (sr)
WO (1) WO2015153304A1 (sr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
AU2015241247B2 (en) 2014-04-01 2017-09-14 Merck Sharp & Dohme Llc Prodrugs of HIV reverse transcriptase inhibitors
CN106008362B (zh) * 2016-05-24 2018-08-10 杰达维(上海)医药科技发展有限公司 一种嘧啶衍生物的制备方法
CA3086303A1 (en) 2017-12-22 2019-06-27 Sumitomo Chemical Company, Limited Heterocyclic compound and harmful arthropod controlling agent containing same
JOP20210149A1 (ar) * 2018-12-18 2023-01-30 Merck Sharp & Dohme مشتقات بيريميدين تعمل كعوامل انتقائية ضد الخلايا المصابة بفيروس نقص المناعة البشرية
EP3928834A4 (en) 2019-02-20 2022-10-12 Sumitomo Chemical Company Limited ETHER COMPOUND AND HARMFUL ARTHROPOD CONTROL COMPOSITION CONTAINING THE SAME
MX2021014247A (es) 2019-05-22 2022-01-06 Merck Sharp & Dohme Llc Derivados piridinona como agentes citotoxicos selectivos contra celulas infectadas con virus de inmunodeficiencia humana (vih).
KR20220034853A (ko) 2019-07-16 2022-03-18 브리스톨-마이어스 스큅 컴퍼니 인터류킨의 조정에서의 전구약물
TW202304919A (zh) 2021-03-31 2023-02-01 印度商皮埃企業有限公司 稠合雜環化合物及其作為害蟲控制劑之用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IT1305313B1 (it) * 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
EA011164B1 (ru) 2003-02-07 2009-02-27 Янссен Фармацевтика Н. В. Производные пиримидина для профилактики вич-инфекции
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
EP1699777B1 (en) * 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7288942B2 (en) * 2003-10-02 2007-10-30 Naoyuki Sato Plasma potential measuring method and apparatus, and plasma potential measuring probe
WO2005070901A2 (en) 2004-01-12 2005-08-04 Gilead Sciences, Inc. Pyrimidyl phosphonate antiviral compounds and methods of use
CA2559552A1 (en) 2004-03-23 2005-09-29 F. Hoffmann-La Roche Ag Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
ES2333802T3 (es) 2004-04-23 2010-03-01 F. Hoffmann-La Roche Ag Inhibidores no nucleicos de transcriptasa inversa.
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
CA2592092A1 (en) 2004-12-22 2006-06-29 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
DE602006005699D1 (de) 2005-10-19 2009-04-23 Hoffmann La Roche N-phenyl-phenylacetamid-nichtnukleosidinhibitoren reverser transkriptase
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
BRPI0719060A2 (pt) 2006-11-24 2014-02-04 Takeda Pharmaceutical Composto, prodroga, agente farmacêutico, métodos para inibir um receptor de angiotensina ii e/ou ativar um receptor ativado com proliferador de peroxisoma, e para prevenir ou tratar doenças ou condições, e, uso de um composto
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
US8404253B2 (en) 2006-12-28 2013-03-26 Newport Laboratories, Inc. Modified live (JMSO strain) Haemophilus parasuis vaccine
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
RU2010125220A (ru) * 2007-11-20 2011-12-27 Мерк Шарп Энд Домэ Корп. (Us) Ненуклеозидные ингибиторы обратной транскриптазы
CN103254138A (zh) * 2008-01-08 2013-08-21 默沙东公司 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法
WO2011120133A1 (en) * 2010-03-30 2011-10-06 Merck Frosst Canada Ltd. Non-nucleoside reverse transcriptase inhibitors
WO2011126969A1 (en) 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Prodrugs of an hiv reverse transcriptase inhibitor
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
AU2015241247B2 (en) 2014-04-01 2017-09-14 Merck Sharp & Dohme Llc Prodrugs of HIV reverse transcriptase inhibitors

Also Published As

Publication number Publication date
HUE051848T2 (hu) 2021-03-29
PL3125894T3 (pl) 2021-02-08
LT3125894T (lt) 2020-12-10
JP6342011B2 (ja) 2018-06-13
MX2016012915A (es) 2016-12-07
DK3125894T3 (da) 2020-11-16
EP3785714A1 (en) 2021-03-03
US20170173015A1 (en) 2017-06-22
PT3125894T (pt) 2020-11-05
RU2016142611A3 (sr) 2018-12-26
CA2944187C (en) 2018-06-19
HRP20201780T1 (hr) 2021-06-25
ES2828951T3 (es) 2021-05-28
CN106456639A (zh) 2017-02-22
EP3125894B1 (en) 2020-09-09
BR112016022722B8 (pt) 2023-11-21
CY1123582T1 (el) 2022-03-24
EP3125894A1 (en) 2017-02-08
AU2015241247B2 (en) 2017-09-14
US10004740B2 (en) 2018-06-26
BR112016022722A2 (pt) 2017-10-31
KR20160133000A (ko) 2016-11-21
RU2016142611A (ru) 2018-05-03
KR102440843B1 (ko) 2022-09-29
BR112016022722B1 (pt) 2023-03-07
SI3125894T1 (sl) 2020-12-31
CN106456639B (zh) 2019-05-10
WO2015153304A1 (en) 2015-10-08
EP3125894A4 (en) 2017-12-13
CA2944187A1 (en) 2015-10-08
RU2693622C2 (ru) 2019-07-03
JP2017512802A (ja) 2017-05-25
AU2015241247A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
IL247923A0 (en) 4-substituted nucleotide derivatives as HIV reverse transcriptase inhibitors
IL251584A0 (en) Dihydropyrrolopyridines ror-gamma inhibitors
IL246902B (en) Dihydropyrrolopyridine ror–gamma inhibitors
ZA201604272B (en) Inhibitors of glutaminase
PL3125894T3 (pl) Proleki inhibitorów odwrotnej transkryptazy hiv
EP3494971C0 (en) SALTS OF ERK INHIBITORS
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
HK1256902A1 (zh) 氯犬尿氨酸的前體藥物
RS61947B1 (sr) Davanje selektivnog inhibitora il-6-trans-signalizacije
GB201402169D0 (en) Viral inhibitors
GB201401005D0 (en) Inhibitor
HUP1500506A2 (en) Salts of palbociclib
GB201417347D0 (en) Prodrugs of delanzomib
GB201417348D0 (en) Prodrugs of lxazomib
TH1501005447A (th) สารยับยั้ง ido
GB201417192D0 (en) Deposition of graphene
GB201418154D0 (en) Inhibitors